Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
Identifieur interne : 004A78 ( Main/Exploration ); précédent : 004A77; suivant : 004A79Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
Auteurs : O. Rascol [France] ; N. Fabre [France] ; O. Blin ; J. Poulik [France] ; U. Sabatini [France] ; J.-M. Senard [France] ; M. Ane [France] ; J.-L. Montastruc [France] ; A. RascolSource :
- Movement disorders [ 0885-3185 ] ; 1994.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Antagonist, Antiparkinson agent, Bromocriptine (adverse effects), Bromocriptine (therapeutic use), Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Double blind study, Double-Blind Method, Drug Therapy, Combination, Dyskinesia, Drug-Induced (drug therapy), Female, Human, Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Morphinan derivatives, Motor Skills (drug effects), Naltrexone (adverse effects), Naltrexone (therapeutic use), Neurologic Examination (drug effects), Opiates, Parkinson Disease (drug therapy), Parkinson disease, Treatment.
- MESH :
- chemical , adverse effects : Bromocriptine, Levodopa, Naltrexone.
- chemical , therapeutic use : Bromocriptine, Levodopa, Naltrexone.
- drug effects : Motor Skills, Neurologic Examination.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- Aged, Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.
Affiliations:
- France
- Midi-Pyrénées, Occitanie (région administrative), Provence-Alpes-Côte d'Azur
- Marseille, Toulouse
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001941
- to stream PascalFrancis, to step Curation: 001711
- to stream PascalFrancis, to step Checkpoint: 001792
- to stream Main, to step Merge: 005436
- to stream PubMed, to step Corpus: 001673
- to stream PubMed, to step Curation: 001632
- to stream PubMed, to step Checkpoint: 001632
- to stream Ncbi, to step Merge: 001D06
- to stream Ncbi, to step Curation: 001D06
- to stream Ncbi, to step Checkpoint: 001D06
- to stream Main, to step Merge: 005250
- to stream Main, to step Curation: 004A78
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM Univ. hosp., dep. clinical pharmacology</s1><s2>31073 Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1><s2>31073 Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name></author><author><name sortKey="Poulik, J" sort="Poulik, J" uniqKey="Poulik J" first="J." last="Poulik">J. Poulik</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1><s2>31073 Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Sabatini, U" sort="Sabatini, U" uniqKey="Sabatini U" first="U." last="Sabatini">U. Sabatini</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1><s2>31073 Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J.-M." last="Senard">J.-M. Senard</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM Univ. hosp., dep. clinical pharmacology</s1><s2>31073 Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Ane, M" sort="Ane, M" uniqKey="Ane M" first="M." last="Ane">M. Ane</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Univ. hosp., dep. clinical pharmacology</s1><s2>Marseille</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J.-L." last="Montastruc">J.-L. Montastruc</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM Univ. hosp., dep. clinical pharmacology</s1><s2>31073 Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1><s2>31073 Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">94-0662072</idno><date when="1994">1994</date><idno type="stanalyst">PASCAL 94-0662072 INIST</idno><idno type="RBID">Pascal:94-0662072</idno><idno type="wicri:Area/PascalFrancis/Corpus">001941</idno><idno type="wicri:Area/PascalFrancis/Curation">001711</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001792</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001792</idno><idno type="wicri:doubleKey">0885-3185:1994:Rascol O:naltrexone:an:opiate</idno><idno type="wicri:Area/Main/Merge">005436</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:7969211</idno><idno type="wicri:Area/PubMed/Corpus">001673</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001673</idno><idno type="wicri:Area/PubMed/Curation">001632</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001632</idno><idno type="wicri:Area/PubMed/Checkpoint">001632</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001632</idno><idno type="wicri:Area/Ncbi/Merge">001D06</idno><idno type="wicri:Area/Ncbi/Curation">001D06</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D06</idno><idno type="wicri:doubleKey">0885-3185:1994:Rascol O:naltrexone:an:opiate</idno><idno type="wicri:Area/Main/Merge">005250</idno><idno type="wicri:Area/Main/Curation">004A78</idno><idno type="wicri:Area/Main/Exploration">004A78</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM Univ. hosp., dep. clinical pharmacology</s1><s2>31073 Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1><s2>31073 Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name></author><author><name sortKey="Poulik, J" sort="Poulik, J" uniqKey="Poulik J" first="J." last="Poulik">J. Poulik</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1><s2>31073 Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Sabatini, U" sort="Sabatini, U" uniqKey="Sabatini U" first="U." last="Sabatini">U. Sabatini</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1><s2>31073 Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J.-M." last="Senard">J.-M. Senard</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM Univ. hosp., dep. clinical pharmacology</s1><s2>31073 Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Ane, M" sort="Ane, M" uniqKey="Ane M" first="M." last="Ane">M. Ane</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Univ. hosp., dep. clinical pharmacology</s1><s2>Marseille</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J.-L." last="Montastruc">J.-L. Montastruc</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM Univ. hosp., dep. clinical pharmacology</s1><s2>31073 Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1><s2>31073 Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="1994">1994</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antagonist</term><term>Antiparkinson agent</term><term>Bromocriptine (adverse effects)</term><term>Bromocriptine (therapeutic use)</term><term>Cross-Over Studies</term><term>Disability Evaluation</term><term>Dose-Response Relationship, Drug</term><term>Double blind study</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Female</term><term>Human</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Morphinan derivatives</term><term>Motor Skills (drug effects)</term><term>Naltrexone (adverse effects)</term><term>Naltrexone (therapeutic use)</term><term>Neurologic Examination (drug effects)</term><term>Opiates</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Treatment</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term><term>Levodopa</term><term>Naltrexone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bromocriptine</term><term>Levodopa</term><term>Naltrexone</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cross-Over Studies</term><term>Disability Evaluation</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term><term>Naltrexone</term><term>Antagoniste</term><term>Opiacés</term><term>Antiparkinsonien</term><term>Traitement</term><term>Homme</term><term>Etude double insu</term><term>Morphinane dérivé</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader></TEI><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li><li>Provence-Alpes-Côte d'Azur</li></region><settlement><li>Marseille</li><li>Toulouse</li></settlement></list><tree><noCountry><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name></noCountry><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name></region><name sortKey="Ane, M" sort="Ane, M" uniqKey="Ane M" first="M." last="Ane">M. Ane</name><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J.-L." last="Montastruc">J.-L. Montastruc</name><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J.-L." last="Montastruc">J.-L. Montastruc</name><name sortKey="Poulik, J" sort="Poulik, J" uniqKey="Poulik J" first="J." last="Poulik">J. Poulik</name><name sortKey="Sabatini, U" sort="Sabatini, U" uniqKey="Sabatini U" first="U." last="Sabatini">U. Sabatini</name><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J.-M." last="Senard">J.-M. Senard</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A78 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004A78 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:94-0662072
|texte= Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |